Defensin (HBD-3) vs LL-37 — Peptide Comparison

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

At a Glance

Quickcomparison

Dose Range

Defensin (HBD-3)

1–50 μg/mL (research)

LL-37

0.5–1.6 mg/mL (topical)

Frequency

As needed

Once daily

Administration

Topical application (research/wound care)

Topical application (wound healing)

Cycle Length

Ongoing/indefinite

12+ weeks

Onset Speed

Rapid (hours to days)

Moderate (1-2 weeks)

Evidence Level

Moderate human trials (Phase 1-2)

Efficacy

Benefitratings

Fighting Drug-Resistant Bacteria

Wound Healing

Immune System Support

Fighting Infections

Immune Boost

Technical Data

Compoundspecifications

Molecular Formula

Approximately C220H340N64O62S6 (45-amino acid peptide with 3 disulfide bonds)

Molecular Weight

~5,155 Da (mature peptide)

Half-Life

Short systemic half-life (minutes) typical of cationic peptides; disulfide-bonded form provides protease resistance at local tissue sites; linear form shows adequate stability for topical applications

Bioavailability

Topical application achieves high local concentrations; maintains activity in physiological salt environments (unique); linear form retains activity enabling simplified formulation; not intended for oral or systemic delivery

CAS Number

Not assigned (endogenous human peptide; research-grade available from peptide suppliers)

C205H340N60O53

4,493.26 Da

Short systemic half-life (minutes) due to protease susceptibility; local tissue persistence at wound sites is longer due to binding to extracellular matrix components and lipid membranes

Topical application achieves high local wound-bed concentrations; systemic bioavailability limited by rapid proteolytic degradation and serum protein binding; not intended for oral delivery

154947-66-7

Protocols

Dosingtiers

standard

200 µg/mL applied to the wound, about 4 µg per dose (20 µL)

Every 2 days in the study

Until wound healed (study setting)

HBD-3 is a research-only peptide with no human dosing protocol. This amount comes from a preclinical infected-diabetic-wound study where it was applied to the wound surface and sped up healing while lowering bacteria [6]. Human use has not been established.

starting

0.5 mg/mL gel

Twice weekly

4 weeks

Lowest dose in the LL-37 (ropocamptide) Phase I/IIa venous leg-ulcer trial and the most effective: ~6-fold faster healing and ~68% ulcer-area reduction vs placebo, applied to the wound twice weekly [4].

1.6 mg/mL gel

Mid dose in the same trial; ~3-fold improvement and ~50% area reduction vs placebo. The highest tested concentration (3.2 mg/mL) showed no benefit over placebo, so dose escalation above this is not supported [4].

Applications

Bestsuited for

Research into anti-MRSA therapeutics and alternatives to vancomycin for resistant infections

Defensin (HBD-3) is particularly well-suited for individuals focused on research into anti-mrsa therapeutics and alternatives to vancomycin for resistant infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Development of antimicrobial wound dressings and medical device coatings

Defensin (HBD-3) is particularly well-suited for individuals focused on development of antimicrobial wound dressings and medical device coatings. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Anti-biofilm strategies for chronic wound infections and implant-associated infections

Defensin (HBD-3) is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and implant-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Applications requiring antimicrobial activity in physiological or high-salt environments

Defensin (HBD-3) is particularly well-suited for individuals focused on applications requiring antimicrobial activity in physiological or high-salt environments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers

LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)

LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Anti-biofilm strategies for chronic wound infections and medical device-associated infections

LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Boosting innate immune defense in immunocompromised or aging individuals

LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Sideeffects

Common

Local site irritation

Transient inflammatory response

Mild wound bed changes

Uncommon

Localized allergic reaction

Mild cytotoxicity at high concentrations

Serious

No serious adverse effects documented at therapeutic concentrations

Transient stinging or burning

Mild perilesional erythema

Increased wound exudate

Allergic contact reaction

Hemolytic activity at systemic concentrations

Research Status

Safety& evidence

FDA Status

Research compound

Safety Overview

Defensin HBD-3 is not FDA-approved and has no completed human clinical trials, existing only in research contexts with in vitro and animal study data. Animal toxicology studies demonstrate no major systemic toxicity at doses exceeding therapeutic levels, but human immunological responses to exogenously administered defensin peptides have not been characterized. Risks include potential immune activation, cross-reactivity with self-antigens (due to HBD-3 expression in healthy epithelial cells), development of anti-peptide antibodies, and possible tolerance development with repeated dosing. Bacterial and fungal resistance to defensin-based therapy is theoretically possible. No human pharmacokinetics, dose-ranging studies, Phase 1 safety assessments, or clinical efficacy data exist.

Contraindications

xKnown hypersensitivity to defensin peptides or formulation components

xPregnancy and breastfeeding — insufficient safety data for exogenous defensin administration

xActive autoimmune conditions — potential for immune activation through monocyte/macrophage recruitment

xSevere hepatic or renal impairment — peptide clearance may be altered for any systemic exposure

LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications.

xKnown hypersensitivity to cathelicidin peptides or formulation components

xActive hemolytic conditions — LL-37 demonstrates concentration-dependent hemolytic activity

xPregnancy and breastfeeding — insufficient reproductive safety data from clinical trials

xSevere renal impairment — peptide clearance may be altered

Decision Guide

Which isright for you?

Choose Defensin (HBD-3) if...